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Background: Recurrent, metastatic mesenchymal myxoid tumors of the gynecologic tract present a management
challenge as there is minimal evidence to guide systemic therapy. Such tumors also present a diagnostic dilemma,
as myxoid features are observed in leiomyosarcomas, inflammatory myofibroblastic tumors (IMT), and mesenchymal
myxoid tumors. Comprehensive genomic profiling was performed in the course of clinical care on a case of a recurrent,
metastatic myxoid uterine malignancy (initially diagnosed as smooth muscle tumor of uncertain malignant potential
(STUMP)), to guide identify targeted therapeutic options. To our knowledge, this case represents the first report of
clinical response to targeted therapy in a tumor harboring a DCTN1-ALK fusion protein.
Methods: Hybridization capture of 315 cancer-related genes plus introns from 28 genes often rearranged or altered in
cancer was applied to >50 ng of DNA extracted from this sample and sequenced to high, uniform coverage. Therapy
was given in the context of a phase I clinical trial ClinicalTrials.gov Identifier: (NCT01548144).
Results: Immunostains showed diffuse positivity for ALK1 expression and comprehensive genomic profiling identified an
in frame DCTN1-ALK gene fusion. The diagnosis of STUMP was revised to that of an IMT with myxoid features. The patient
was enrolled in a clinical trial and treated with an anaplastic lymphoma kinase (ALK) inhibitor (crizotinib/Xalkori®) and a
multikinase VEGF inhibitor (pazopanib/Votrient®). The patient experienced an ongoing partial response (6+ months) by
response evaluation criteria in solid tumors (RECIST) 1.1 criteria.
Conclusions: For myxoid tumors of the gynecologic tract, comprehensive genomic profiling can identify clinical
relevant genomic alterations that both direct treatment targeted therapy and help discriminate between similar
diagnostic entities.
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Myxoid neoplasms of the uterus are a diverse group of soft
tissue tumors presenting diagnostic dilemmas for patholo-
gists [1]. The mainstay of treatment for uterine myxoid
neoplasms is surgical resection. However, recurrent and
metastatic myxoid neoplasms are challenging to manage
medically due to scant evidence-based guidance. The com-
bination of a challenging diagnostic proposition and only
limited evidence to guide management is a strong rationale
for the use of comprehensive genomic profiling (CGP) in
an effort to uncover clinically relevant genomic alterations
(CRGA) that suggest possible benefit from targeted therapy.
Here, we report the case of a patient with a recurrent,
metastatic uterine myxoid neoplasm staining diffusely for
ALK1 and harboring a DCTN1-ALK fusion identified by
CGP who has experienced clinical and radiographic im-
provement with targeted inhibition of anaplastic lymphoma
kinase (ALK) (crizotibib/Xalkori®) and additional targeted
therapy (pazopanib/Votrient®).Patients and methods
Patient selection and clinical assessments
The team reviewed the medical records of a patient who
presented to the Department of Investigational Cancer
Therapeutics at The University of Texas MD Anderson
Cancer Center following an initial diagnosis of a myxoid
uterine neoplasm. With minimal standard of care options
left, the patient was advised to participate in a clinical trial.
Treatment and consent on the investigational trial and data
collection were performed in accordance with the guide-
lines of The University of Texas MD Anderson Cancer
Center Institutional Review Board (IRB). Tumor response
was determined using response evaluation criteria in solid
tumors (RECIST) (version 1.1) by CT scan obtained every 2
cycles post treatment initiation. Clinical evaluation and as-
sessments were performed per protocol.Genomic profiling
Comprehensive genomic profiling was performed using the
FoundationOne® assay in a Clinical Laboratory Improve-
ment Amendments (CLIA)-certified, CAP-accredited cen-
tral laboratory (Foundation Medicine, Cambridge, MA,
USA). Hybridization capture of 315 cancer-related genes
plus introns from 28 genes often rearranged or altered in
cancer was applied to >50 ng of DNA extracted from this
sample and sequenced to high, uniform coverage. All clas-
ses of genomic alterations, including base substitutions,
small insertions and deletions (indels), rearrangements, and
copy number alterations, were assessed. Clinically relevant
genomic alterations (CRGA) were defined as those suggest-
ing benefit from an approved targeted therapy or directing
benefit from mechanism-based clinical trials.Results and discussion
Case history
A female in her 50’s Gravida 0, with a long standing his-
tory of gynecologic discomfort with history of laparos-
copy and hysteroscopy that showed endometriosis and
uterine fibroids presented to the clinic with increasing
pelvic pressure sensations and significant cramps, symp-
toms concerning for an abdomino-pelvic neoplasm. At
presentation, her disease was described as a 14–16-week
sized globular intra-uterine mass and clinically diag-
nosed as a leiomyoma. Morcellation was performed, and
pathologic examination of the formalin fixed paraffin
embedded (FFPE) morcellated tissue revealed a myxoid
neoplasm, consistent with a smooth muscle tumor of
uncertain malignant potential (STUMP). This pathologic
diagnosis was done at the outside institution. The pa-
tient was subsequently symptomatically monitored for
disease progression. Eight months following diagnosis,
the patient reported pelvic pain and underwent a bilat-
eral salpingo-oophorectomy, pelvic lymphadenectomy,
and omentectomy. Pathologic examination confirmed
metastatic myxoid neoplasm within the pelvis right wall,
peritoneum, bladder, and peritoneal cul-de-sac. The pa-
tient was again monitored, and 7 months later, follow-up
imaging identified a 2-cm mass abutting the right exter-
nal iliac artery. A laparoscopic procedure was performed
and confirmed a recurrence of myxoid tumor. The pa-
tient was followed for 2 years in which disease subse-
quently recurred as a lesion in the liver, multiple vaginal
tumors, and recurrent tumor over the external iliac ar-
tery. These presumed recurrences were biopsied, con-
firmed as recurrent disease, and resected. A decision
was made to investigate systemic treatment, as local
management was not effective.
The patient presented to The University of Texas MD
Anderson Cancer Center for therapy recommendations.
The patient was seen by the gynecological oncologist,
sarcoma medical oncologist, and investigational cancer
therapeutics consultant at the clinical center for targeted
therapy. The natural history of rapid recurrences after
initial local management was clearly inconsistent with a
typical STUMP. The specimens were requested for path-
ology confirmation.
The diagnostic specimen was immunostained and
demonstrated diffuse positivity for ALK as well as posi-
tivity for desmin (Fig. 1). At the same time, this speci-
men was submitted as an FFPE block for comprehensive
genomic profiling [2].
Genomic profiling
Three hundred fifteen cancer-related genes plus select in-
trons from 28 genes often rearranged or altered in solid
tumor cancers were sequenced to a median depth of cover-
age of 481×. A deletion event on chromosome 2 (Fig. 2),
Fig. 1 IMT infiltrating the myometrium are images 1 and 2. The myxoid areas are infiltrating the muscle of the myometrium. Image 3 is an
immunostain for ALK, diffusely positive in the spindle tumor cells
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fied. No other genomic alterations were identified in the
specimen.
Based on the diagnostic results of diffuse ALK expression
indicating an alteration of ALK, the diagnosis was updated
to that of an inflammatory myofibroblastic tumor (IMT)
with myxoid features. The comprehensive genomic profil-
ing confirmed the diagnosis by demonstrating a DCTN1-
ALK fusion.
The patient was presented in the targeted therapy clinical
trials treatment planning meeting, and treatment with an
ALK inhibitor was recommended. At this time, the patient
returned to the Department of Investigational Cancer Ther-
apeutics at The University of Texas MD Anderson Cancer
Center for further treatment discussions including a targeted
therapy consult for ALK inhibitor options. The patient was
enrolled in a phase I clinical trial (ClinicalTrials.gov Identi-
fier: NCT01548144) of crizotinib in combination with pazo-
panib for the treatment of advanced cancer [3]. The patient
was treated with crizotinib 250 mg orally on alternating days
and pazopanib 200 mg orally daily for a 21 day cycle. After
2 cycles of therapy, the patient had greater than 30 % reduc-
tion in the sum of longest diameter (SLD) of target lesions
per RECIST 1.1 (Fig. 4), indicating a partial response to ther-
apy. The patient tolerated the combination therapy well. She
had grade 1 mild diarrhea which was controlled by lopera-
mide and grade 1 nausea which was controlled by ondanse-
tron. At the time of submission, the patient continues tohave a response for over 6 months with significant decrease
in the tumor measurements and is in confirmed partial re-
mission (PR).
Given the revised diagnosis in this case, we wondered if
other advanced uterine neoplasms harbored ALK aberra-
tions and rearrangements. A large series of comprehensive
genomic profiles of advanced uterine leiomyosarcomas
(LMS) obtained in the course of clinical care were analyzed.
Of 139 LMS cases, 5 ALK rearrangements were identified
for a frequency of 3.6 % (Elvin et al., manuscript in prepar-
ation, personal communication).
Discussion
ALK inhibitors are the standard of care for ALK-rear-
ranged non-small cell lung cancer, and the resulting suc-
cess is the paradigm for precision oncology [4]. This case
harbors a DCTN1-ALK fusion which has been previously
reported [5, 6] but is described here in a myxoid uterine
neoplasm for the first time. After multiple recurrences,
ALK immunohistochemistry (IHC) was performed con-
currently with comprehensive genomic profiling (CGP) on
the diagnostic specimen. Based on the tumor harboring
an ALK fusion and the staining for ALK1 by immunohis-
tochemistry, the diagnosis was changed to an inflamma-
tory myofibroblastic tumor (IMT) with myxoid features.
Treatment with a combination of crizotinib and pazopa-
nib was initiated in the context of a clinical trial and
yielded an ongoing partial response for this case.
Fig. 2 Representative genome images from the Integrated Genome Viewer (IGV) alterations for deletion of ALK exon 1–19, and fusion of ALK-DCTN1
demonstrating ALK and DCTN1 fusion found in the patient with inflammatory myofibroblastic tumor with myxoid features who had a response to ALK
inhibitor based therapy
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sion protein were first identified in 1994 with the obser-
vation of nucelophosmin (NPM1)-ALK in anaplastic
large cell lymphoma [7]. More recently, ALK rearrange-
ments have been implicated in a variety of tumor types,Fig. 3 The DCTN1-ALK intra-chromosomal rearrangement detected in this case
vast majority having an ALK intron 19 breakpoint and is a priori suspected to ac
the coiled-coil domains, which is similar to other previously reported ALK fusion
of ALK and subsequent kinase activation by transphosphorylationnotably non-small cell lung carcinoma (NSCLC), inflam-
matory myofibroblastic tumors (IMT), and renal cancer
[4]. Particularly in NSCLC, the presence of an ALK fu-
sion predicts response to crizotinib [4]. The rearrange-
ment observed in this case, DCTN1-ALK, has beenconformed to the common structural organization of ALK fusions, with the
tive in vivo. The DCTN1 component of the fusion contains exons including
partners. Via these domains, DCTN1 is suspected to promote dimerization
Fig. 4 Imaging studies at baseline and follow-up. a Pre-treatment axial CT image shows a 6.2 × 5.1 cm peritoneal implant in the left upper quadrant (top)
and a 4.4 × 4 cm peritoneal implant in the right hepatorenal space (bottom). b Follow-up axial CT image shows interval decrease in the peritoneal implant
in the left upper quadrant which measures 4.5 × 3.8 cm, previously 6.2 × 5.1 cm (top). Axial CT image shows that the 4.4 × 4 cm peritoneal implant in the
right hepatorenal space (bottom) has not changed much in size (measured 4.4 × 3.7 cm), but the lesion has now become less dense. This is an important
observation as this represents response to therapy. Radiologists and clinicians should be aware that many targeted therapies may not result in significant
change in size particularly during the early stages but may cause interval decrease in vascularity; on CT, this may be seen as decrease in density of the
target lesions and represents response to therapy
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tissue of the neck [5] and 6/140 atypical Spitz tumors,
the latter as identified by CGP [6].
The most common mechanism of ALK fusions is a gen-
omic rearrangement involving the ALK locus at 2p23 with
the common breakpoint in intron 19 resulting in the dis-
sociation of the 3′ exons 20–29 from the 5′ exons 1–19
[4]. The DCTN1-ALK intra-chromosomal rearrangement
detected in this case conformed to the common structural
organization of ALK fusions, with the vast majority having
an ALK intron 19 breakpoint, and is a priori suspected to
be active in vivo. The DCTN1 component of the fusion
contains exons 1–29 including coiled-coil domains, which
is structurally similar to other previously reported ALK fu-
sion partners (Figs. 2 and 3). Via these domains, DCTN1
is suspected to promote dimerization of ALK and subse-
quent kinase activation by transphosphorylation [5, 8].
Myxoid neoplasms of the uterus are defined by myxoid
features but can carry a range of diagnoses [9, 10]. Diagno-
ses of such tumors rely on clinicopathologic observations
to formulate an effective differential diagnosis [11]. From
the initial differential, myxoid neoplasms are most often
classified by their clinical behavior—benign, locally aggres-
sive, or malignant nature—as well as by an imputed histo-
genetic origin including myxoid leiomyosarcoma, myxoid
liposarcoma, and myxofibrosarcoma among others [11].In particular, the differential diagnosis for a myxoid neo-
plasm of the uterus must include IMT of the uterus, which
are known to have myxoid features. IMTs are characterized
by myofibroblastic spindle cells accompanied by a lympho-
plasmacytic inflammatory infiltrate [12, 13]. The myxoid
morphologic appearance of an IMT can create diagnostic
challenges, particularly if pauci-inflammatory, and the dif-
ferential includes benign myxoid leiomyoma and malignant
myxoid and inflammatory leiomyosarcoma [14].
The diagnostic challenge associated with differentiating
between uterine myxoid neoplasms and uterine IMT can be
resolved through the identification of kinase fusion events.
Previous data have demonstrated that approximately 50 %
of IMT cases are ALK positive [12, 15, 16]. Additional stud-
ies have showed that of ALK IHC-negative case, 8/11 (73 %)
identified alternate kinase fusions, including 2 cases with
ALK fusions missed by ALK IHC and 6 cases harboring ei-
ther ROS1 (4) or PDGFRβ (2) fusions [13]. The diagnosis of
an IMT with uterine origin is further compounded by its
rarity and nonspecific symptoms; thus, this diagnosis is
commonly overlooked by clinicians [14, 17]. To date, ALK
positive uterine IMTs have been reported using immunohis-
tochemistry and FISH methods, with previous studies show-
ing 100 % [11, 18] and 87.5 % [19] ALK positivity in female
genital tract IMTs, respectively. However, such studies are
limited by the diagnostic criteria used to identify IMTs. If an
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CGP can identify genomic rearrangements of non-ALK ki-
nases, which will strongly support the diagnosis of an
IMT as seen in IMT of soft tissue [13]. Knowledge of the
natural history of IMT, both of uterine origin and other, is
scant. From IMTs located in the lung, 3- and 5-year sur-
vival were 82 and 74 %, respectively, with 15 % of patients
experiencing recurrent disease [20]. No clinical trials for
systemic treatment have focused solely on IMTs, but a re-
cent phase I trial for refractory pediatric solid tumors
demonstrated three of seven ALK-rearranged IMT pa-
tients had partial responses, and another three had stable
disease on crizotinib treatment [21].
Crizotinib is an oral small-molecule tyrosine kinase in-
hibitor that targets the ALK, MET, and ROS1 tyrosine ki-
nases and is well known to induce clinically significant
responses in NSCLC [22–24]. Response to crizotinib in
IMT harboring ALK fusions have also been observed in
two patients [21, 25, 26]. In this case report, we describe
the documented clinical response of a uterine IMT to a
combination of crizotinib and pazopanib. The question re-
mains if response, toxicity, or overall survival benefitted
from combination therapy of crizotinib and pazopanib
compared with crizotinib monotherapy. As exemplified by
trials for BRAF V600E metastatic melanoma, treatment
with dabrafenib monotherapy versus the combination of
dabrafenib and trametinib in BRAF V600E mutated melan-
oma [27] can significantly improve overall survival without
increasing overall toxicities. Crizotinib has been shown to
be superior to standard chemotherapy in advanced non-
small-cell lung cancer [28] and is approved as the first line
therapy for ALK-rearranged metastatic NSCLC.
However, acquired resistance to crizotinib monother-
apy is well demonstrated in the setting of NSCLC, and a
similar phenomenon may arise in ALK-rearranged IMT
treated with crizotinib [29]. Pazopanib is a multikinase
inhibitor with activity against VEGFR1-3, PDGFRA and
PDGFRB, FGFR1 and FGFR3, and c-Kit [30]. Whether
the combination of crizotinib or pazopanib is synergistic,
additive, or deleterious is unknown, and the continuing
outcome of the patient may anecdotally address this issue.
Arguably, pazopanib is likely to further inhibit signaling
downstream of the above receptor tyrosine kinases [30].
This depression of signaling may further benefit the case
by inhibiting pathways of acquired resistance akin to PI3K
inhibitors and crizotinib in ALK-rearranged NSCLC but
would need to be explored rigorously in vitro to prove this
possibility.
Conclusions
This report demonstrates the first documented response of
a myxoid tumor of the female genital tract harboring an
ALK fusion to combination therapy including ALK-targeted
therapy. To our knowledge, this case represents the firstreport of clinical response to targeted therapy in a tumor
harboring a DCTN1-ALK fusion protein. This report not
only demonstrates the difficulty in diagnosing rare tumors
in uterine soft tissue but also emphasizes the use of com-
prehensive genomic profiling for identifying clinically rele-
vant genomic alterations, such as ALK rearrangements, and
immediate implications for patient benefit.
Findings
 DCTN1-ALK fusion, previously reported in an
inflammatory myofibroblastic tumor (IMT) and
Spitz tumors, is described here in a myxoid
neoplasm of the female reproductive tract.
 This case is the first report of a tumor harboring
DCTN1-ALK being treated with combination
targeted therapy with a documented clinical and
radiographic response.
 Comprehensively genomic profiling can uncover
clinically relevant genomic alterations in rare
tumors, such as myxoid uterine neoplasms, that
present diagnostic challenges to pathologic and
while simultaneously providing unanticipated
pathways to benefit from targeted therapy.
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